These findings suggest that LSD1 may serve as a dual regulator, influencing PD‐L1 expression in tumour cells and the infiltration of CD8+ T cells in the TME, ultimately determining sensitivity to ICB therapy. This evidence concerns the gene KDM1A and neoplasm.